Pharmaceutical

OptiNose (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common stock. The offering is expected to consist of 2,250,000 shares to be offered by Optinose and 2,250,000 shares to be offered …

OptiNose (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common stock. The offering is expected to consist of 2,250,000 shares to be offered by Optinose and 2,250,000 shares to be offered by certain selling stockholders.

As quoted in the press release:

In addition, Optinose and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 675,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Jefferies and Piper Jaffray will act as the lead joint book-running managers for the offering. BMO Capital Markets and RBC Capital Markets will also act as joint book-running managers for the offering and Cantor will act as sole lead manager.

Click here to read the full press release.

MARKETS

Markets
TSX18982.92-79.93
TSXV607.97-8.28
DOW31899.29-137.61
S&P 5003961.63-37.32
NASD11834.11-225.50
ASX6791.50-2.80

COMMODITIES

Commodities
Gold1725.27-1.24
Silver18.56-0.02
Copper3.33-0.02
Palladium2043.50+23.50
Platinum876.00+2.99
Oil95.08+0.38
Heating Oil3.42+0.03
Natural Gas8.50+0.20

DOWNLOAD FREE REPORTS

×